ACTO EXPANDS INVESTMENT IN ARTIFICIAL INTELLIGENCE TO SOLVE UNMET NEEDS IN THE LIFE SCIENCES INDUSTRY
ACTO
SEPTEMBER 11, 2024
“The life sciences industry is actively looking for new ways to leverage AI to bring drugs to market faster to patients waiting in need,” said Parth Khanna, CEO of ACTO. We see ACTO as a category leader with their powerful AI-first platform, which empowers pharma companies to consistently turn their field reps into top performers.
Let's personalize your content